

EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)

NCT07047703

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Grey Wolf Therapeutics
Enrollment	141 participants

Key Eligibility Criteria

Inclusion (27)

- Healthy Volunteers
- Healthy male and female subjects aged 18-55 years inclusive, at the Screening visit
- Participant must provide written informed consent to participate in the study
- Participant must be able and willing to comply with the requirements of the protocol (including dietary restrictions and exclusion of grapefruit juice)
- Male participants (and their female partners) / female participants must be willing to adhere to contraception requirements as detailed in the protocol

... and 22 more (see full listing online)

Exclusion (17)

- Healthy Volunteers
- History or presence of any clinically significant findings in medical history, physical examination, vital signs and/or laboratory tests that, in the opinion of the Investigator, would preclude inclusion in the study
- Participation in a New Chemical Entity clinical study within the previous 124 days or a marketed drug clinical study within the previous 93 days
- Known infection or lifestyle risk factors for human immunodeficiency virus (HIV) and/or hepatitis B or C infection, as determined at the Screening visit
- AxSpA Participants

... and 12 more (see full listing online)

Locations (12 total)

University of the Sunshine Coast (UniSC), Birtinya, Australia
University of the Sunshine Coast (UniSC), Morayfield, Australia
Pioneer Clinical Research, Sydney, Australia

... and 9 more locations